To date, IL-17A blockade shows therapeutic effects on several autoimmune diseases, including psoriasis, RA, psoriatic arthritis, and ankylosing spondylitis (7, 8); however, development of therapeutic treatment for SLE is very challenging because of disease complexity and heterogeneity (1). The gene discussed is IL17A; the disease is psoriasis.